دورية أكاديمية
أعرض في EDS

Predictive capacity of immune-related adverse events and cytokine profiling in neoadjuvant immune checkpoint inhibitor trials for head and neck squamous cell carcinoma.

التفاصيل البيبلوغرافية
العنوان: Predictive capacity of immune-related adverse events and cytokine profiling in neoadjuvant immune checkpoint inhibitor trials for head and neck squamous cell carcinoma.
المؤلفون: Alnemri AE; Department of Otolaryngology - Head & Neck Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA., Tekumalla S; Department of Otolaryngology - Head & Neck Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA., Moroco AE; Department of Otolaryngology - Head & Neck Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA., Vathiotis I; Department of Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA., Tuluc M; Department of Pathology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA., Gargano S; Department of Pathology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA., Zhan T; Department of Biostatistics, Thomas Jefferson University, Philadelphia, Pennsylvania, USA., Cognetti DM; Department of Otolaryngology - Head & Neck Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA., Curry JM; Department of Otolaryngology - Head & Neck Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA., Argiris A; Department of Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA., Linnenbach A; Department of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA., South AP; Department of Otolaryngology - Head & Neck Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.; Department of Pharmacology, Physiology and Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA., Harshyne LA; Department of Microbiology & Immunology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA., Johnson JM; Department of Otolaryngology - Head & Neck Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.; Department of Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA., Luginbuhl AJ; Department of Otolaryngology - Head & Neck Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
المصدر: Cancer medicine [Cancer Med] 2024 Jun; Vol. 13 (11), pp. e7370.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print Cited Medium: Internet ISSN: 2045-7634 (Electronic) Linking ISSN: 20457634 NLM ISO Abbreviation: Cancer Med Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [Malden, MA] : John Wiley & Sons Ltd., c2012-
مواضيع طبية MeSH: Squamous Cell Carcinoma of Head and Neck*/drug therapy , Squamous Cell Carcinoma of Head and Neck*/blood , Squamous Cell Carcinoma of Head and Neck*/immunology , Immune Checkpoint Inhibitors*/adverse effects , Immune Checkpoint Inhibitors*/therapeutic use , Neoadjuvant Therapy*/adverse effects , Neoadjuvant Therapy*/methods , Cytokines*/blood , Head and Neck Neoplasms*/drug therapy , Head and Neck Neoplasms*/blood , Head and Neck Neoplasms*/immunology, Humans ; Male ; Female ; Middle Aged ; Retrospective Studies ; Aged ; Nivolumab/adverse effects ; Nivolumab/therapeutic use
مستخلص: Objectives: Certain low-level immune-related adverse events (irAEs) have been associated with survival benefits in patients with various solid tumors on immune checkpoint inhibitors (ICIs). We aimed to investigate the association between irAEs and response to neoadjuvant ICIs in patients with head and neck squamous cell carcinoma (HNSCC) and to identify differences in circulating cytokine levels based on irAE status.
Methods: This was a retrospective cohort study including three neoadjuvant clinical trials from July 2017 to January 2022: NCT03238365 (nivolumab ± tadalafil), NCT03854032 (nivolumab ± BMS986205), NCT03618654 (durvalumab ± metformin). The presence and type of irAEs, pathologic treatment response, and survival were compared. Canonical linear discriminant analysis (LDA) was performed to identify combinations of circulating cytokines predictive of irAEs using plasma sample multiplex assay.
Results: Of 113 participants meeting inclusion criteria, 32 (28.3%) developed irAEs during treatment or follow-up. Positive p16 status was associated with irAEs (odds ratio [OR] 2.489; 95% CI 1.069-6.119; p = 0.043). irAEs were associated with pathologic treatment response (OR 3.73; 95% CI 1.34-10.35; p = 0.011) and with higher OS in the combined cohort (HR 0.319; 95% CI 0.113-0.906; p = 0.032). Patients with irAEs within the nivolumab cohort had significant elevations of select cytokines pre-treatment. Canonical LDA identified key drivers of irAEs among all trials, which were highly predictive of future irAE status.
Conclusions: irAEs are associated with response to neoadjuvant ICI therapy in HNSCC and can serve as clinical indicators for improved clinical outcomes. irAEs can be predicted by concentrations of several circulating cytokines prior to treatment.
(© 2024 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd.)
References: Oncologist. 2018 Nov;23(11):1358-1365. (PMID: 29934411)
Eur J Cancer. 2020 Nov;140:55-62. (PMID: 33045663)
JAMA Oncol. 2018 Mar 01;4(3):374-378. (PMID: 28975219)
J Immunother Cancer. 2019 Nov 15;7(1):306. (PMID: 31730012)
Cancer Med. 2024 Jun;13(11):e7370. (PMID: 38847087)
Clin Ther. 2019 Jan;41(1):59-67. (PMID: 30528047)
J Oncol. 2022 Sep 16;2022:8112190. (PMID: 36157224)
J Thorac Dis. 2020 May;12(5):2706-2712. (PMID: 32642178)
Oral Oncol. 2020 Feb;101:104525. (PMID: 31863963)
Nat Immunol. 2021 Jun;22(6):746-756. (PMID: 34031618)
Cancers (Basel). 2020 Apr 25;12(5):. (PMID: 32344813)
J Immunother Cancer. 2020 Oct;8(2):. (PMID: 33020238)
Inflamm Bowel Dis. 2019 Feb 21;25(3):524-531. (PMID: 30544140)
Br J Cancer. 2019 Jan;120(1):6-15. (PMID: 30413827)
Molecules. 2021 Sep 24;26(19):. (PMID: 34641331)
Front Immunol. 2021 Jul 22;12:670391. (PMID: 34367136)
Exp Mol Med. 2018 Dec 13;50(12):1-11. (PMID: 30546008)
Front Immunol. 2023 Feb 20;14:1104771. (PMID: 36891319)
Front Oncol. 2022 Jan 07;11:756902. (PMID: 35070967)
Int Immunol. 2009 Dec;21(12):1303-9. (PMID: 19819937)
Cell. 2018 Nov 1;175(4):998-1013.e20. (PMID: 30388456)
J Exp Clin Cancer Res. 2020 Dec 14;39(1):284. (PMID: 33317597)
JCI Insight. 2020 Jan 30;5(2):. (PMID: 31855576)
Clin Exp Pharmacol Physiol. 2018 Aug;45(8):747-754. (PMID: 29655253)
J Clin Invest. 2007 Apr;117(4):871-3. (PMID: 17404615)
J Allergy Clin Immunol. 2011 Mar;127(3):701-21.e1-70. (PMID: 21377040)
Cytokine Growth Factor Rev. 2013 Feb;24(1):51-7. (PMID: 22906768)
Cancers (Basel). 2020 Nov 18;12(11):. (PMID: 33218183)
JAMA. 2018 Oct 23;320(16):1702-1703. (PMID: 30286224)
Cancer Immunol Immunother. 2019 Jan;68(1):97-107. (PMID: 30311027)
Lung Cancer. 2018 Jan;115:71-74. (PMID: 29290265)
J Cancer Res Clin Oncol. 2019 Oct;145(10):2625-2631. (PMID: 31492984)
JAMA Oncol. 2020 Dec 1;6(12):1952-1956. (PMID: 33119034)
Front Oncol. 2020 Dec 02;10:566315. (PMID: 33344227)
Nat Immunol. 2019 Nov;20(11):1556. (PMID: 31582823)
JAMA Oncol. 2018 Dec 1;4(12):1721-1728. (PMID: 30242316)
J Cancer Res Clin Oncol. 2019 Feb;145(2):511-521. (PMID: 30539281)
Biomed Pharmacother. 2020 Sep;129:110457. (PMID: 32887027)
JAMA Dermatol. 2022 Feb 01;158(2):189-193. (PMID: 35019948)
Cancer Immunol Immunother. 2022 Aug;71(8):1795-1812. (PMID: 35022907)
Cancer. 2021 Dec 15;127(24):4565-4573. (PMID: 34547103)
Clin Cancer Res. 2019 Mar 1;25(5):1452-1454. (PMID: 30587548)
Clin Cancer Res. 2022 Mar 01;28(5):915-927. (PMID: 34911681)
Oral Oncol. 2020 Dec;111:105013. (PMID: 32977184)
J Gastrointest Oncol. 2022 Dec;13(6):2779-2788. (PMID: 36636073)
BMC Med. 2020 Apr 20;18(1):87. (PMID: 32306958)
Int J Biochem Cell Biol. 2004 Oct;36(10):1882-6. (PMID: 15203102)
Br J Cancer. 2019 Jan;120(1):63-68. (PMID: 30377338)
J Clin Oncol. 2019 Oct 20;37(30):2730-2737. (PMID: 31116675)
Cancer Treat Rev. 2021 Jan;92:102134. (PMID: 33302134)
J Immunother Cancer. 2021 Jun;9(6):. (PMID: 34083421)
Clin Cancer Res. 2019 Mar 1;25(5):1557-1563. (PMID: 30409824)
Oncoimmunology. 2019 Mar 27;8(6):e1593810. (PMID: 31069160)
J Transl Med. 2020 Apr 21;18(1):176. (PMID: 32316978)
معلومات مُعتمدة: 5P30CA056036-18 Biostatistics Shared Resource at the Sidney Kimmel Cancer Center - Jefferson Health
فهرسة مساهمة: Keywords: cytokines; head and neck neoplasms; immunotherapy; tumor biomarkers
المشرفين على المادة: 0 (Immune Checkpoint Inhibitors)
0 (Cytokines)
31YO63LBSN (Nivolumab)
تواريخ الأحداث: Date Created: 20240607 Date Completed: 20240607 Latest Revision: 20240611
رمز التحديث: 20240612
مُعرف محوري في PubMed: PMC11157197
DOI: 10.1002/cam4.7370
PMID: 38847087
قاعدة البيانات: MEDLINE
الوصف
تدمد:2045-7634
DOI:10.1002/cam4.7370